Onasemnogene Abeparvovec-xioi
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Spinal Muscular Atrophy
Conditions
Spinal Muscular Atrophy
Trial Timeline
Dec 14, 2017 → Nov 18, 2021
NCT ID
NCT03381729About Onasemnogene Abeparvovec-xioi
Onasemnogene Abeparvovec-xioi is a phase 1 stage product being developed by Novartis for Spinal Muscular Atrophy. The current trial status is terminated. This product is registered under clinical trial identifier NCT03381729. Target conditions include Spinal Muscular Atrophy.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04042025 | Phase 3 | Active |
| NCT03837184 | Phase 3 | Completed |
| NCT03461289 | Phase 3 | Completed |
| NCT03505099 | Phase 3 | Completed |
| NCT03381729 | Phase 1 | Terminated |
| NCT03306277 | Phase 3 | Completed |
| NCT03421977 | Pre-clinical | Active |
Competing Products
20 competing products in Spinal Muscular Atrophy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SUN13837 injection + Placebo | Daiichi Sankyo | Phase 2 | 52 |
| Placebo + Reldesemtiv 150 mg + Reldesemtiv 450 mg | Astellas Pharma | Phase 2 | 52 |
| Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells | Sun Pharmaceutical | Phase 2 | 52 |
| Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells | Sun Pharmaceutical | Phase 1 | 33 |
| Elezanumab | AbbVie | Pre-clinical | 23 |
| Elezanumab + Placebo | AbbVie | Phase 2 | 52 |
| Ropivacaine + Bupivacaine | AstraZeneca | Phase 3 | 77 |
| Zolgensma | Novartis | Pre-clinical | 23 |
| BVS857 + Placebo | Novartis | Phase 2 | 52 |
| AVXS-101 | Novartis | Phase 1 | 33 |
| Onasemnogene Abeparvovec-xioi | Novartis | Phase 3 | 77 |
| Onasemnogene Abeparvovec-brve | Novartis | Approved | 85 |
| Onasemnogene Abeparvovec-xioi | Novartis | Pre-clinical | 23 |
| Onasemnogene Abeparvovec-xioi | Novartis | Phase 3 | 77 |
| branaplam | Novartis | Phase 1/2 | 41 |
| Onasemnogene Abeparvovec-xioi | Novartis | Phase 3 | 77 |
| onasemnogene abeparvovec | Novartis | Phase 3 | 77 |
| onasemnogene abeparvovec-xioi | Novartis | Phase 3 | 77 |
| Risdiplam | Roche | Phase 1 | 33 |
| ATI355 | Novartis | Phase 1 | 33 |